Ketamine Treatment

Ketamine is an FDA-approved medication first synthesized in 1962 and was later approved for use as an anesthetic medication in 1970. It is a blocker of the cellular NMDA receptor, a neural receptor for glutamate that has proven to play a significant role in major depression, chronic pain syndromes, fibromyalgia, and other conditions. It is also known to have potent anti-inflammatory properties and to stimulate neuronal growth, synaptogenesis, and neuroplasticity. It is a Schedule III drug and should only be used and administered by a skilled and licensed anesthesiologist, nurse anesthetist, or trained physician.

The literature for depression shows a 70% success rate. Individual clinics have seen higher rates, because they have seen increased efficacy with increased dosing.

The low doses used for depression are in the empathogenic "heart opening" psychedelic dose range. People report feelings of love, peace, compassion, forgiveness, and a touch of euphoria.

Ketamine will not be provided to individuals with schizophrenia, psychosis, or certain seizure disorders. Those taking aminophylline for asthma or COPD should not undergo ketamine infusions. If you have serious medical problems like uncontrolled high blood pressure, cardiac disease, or pulmonary problems, a clearance will be requested from your primary care physician before undergoing treatment.